MariMed (OTC: MRMD)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
MariMed Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
MariMed Company Info
News & Analysis
The upside these stocks possess may significantly outweigh their risks.
Legalization doesn't matter as much as it may seem.
They've already started down the road -- now they just need to follow through.
They're small now, but these multistate operators look well-placed to rocket ahead in the marijuana market.
Although they've been generating strong numbers in 2021, next year these businesses should do even better.
MariMed and Gage Growth are smaller cannabis companies that are posting big revenue gains. Investors looking for growth might want to get in on these two stocks before they're discovered.
The company is coming off a terrific quarter with strong sales and profit numbers, and there is more growth ahead.
In terms of adjusted EBITDA, these are dirt-cheap buys.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/30/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.